Block Listing Six Monthly Return
Updated : 16:30
14 September 2020
4D pharma plc
(the "Company" or "4D")
Block Listing Six Monthly Return
Name of applicant: | 4D Pharma plc | |||
Name of scheme: | Block Admission for February 2020 warrants | |||
Period of return: | From: | 10 March 2020 | To: | 9 September 2020 |
Number of securities originally admitted at date of admission: | 22,000,000 Ordinary Shares of 0.25p each on 10 March 2020 | |||
Balance of unallotted securities under scheme(s) from previous return: | 22,000,000 Ordinary shares | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 Ordinary shares | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 0 Ordinary shares | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 22,000,000 Ordinary shares | |||
Name of contact: | Duncan Peyton |
Telephone number of contact: | Company Secretary (0113 895 0130) |
Contact Information:
4D
Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130
Investor Relations ir@4dpharmaplc.com
N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000
Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson / Phil Walker
Image Box Communications
Neil Hunter / Michelle Boxall +44 (0)20 8943 4685
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.